



FOR IMMEDIATE RELEASE

Contact:
Jennifer Guinan
Sage Strategic Marketing
610-410-8111
Jennifer@sagestrat.com

Human Capital Consulting Partners Adds Evotec to Client List

Philadelphia, Pa., October 17, 2007—[Human Capital Consulting Partners](#) today announced a new human capital consulting contract with [Evotec AG](#), a leader in the discovery and development of novel small molecule drugs, headquarter in Hamburg, Germany. Human Capital Consulting Partners will assist Evotec AG with the human resources due diligence and employee communication for its first acquisition in the US.

"A vital component of any acquisition is to effectively integrate the human capital assets of the two organizations," said Jim Geier, President of Human Capital Consulting Partners. "At Human Capital Consulting Partners, we assist companies like Evotec AG develop the 'people and integration strategies that drive business growth and make two organizations a better combined force in the marketplace."

Three Neshaminy Interplex
Suite 301
Trevose, PA 19053
Office: 215-244-8110
Fax: 215-245-4705

About Human Capital Consulting Partners

Human Capital Consulting Partners helps companies grow by aligning their human capital strategy with their business strategy. The firm advises companies how to attract, develop, engage, and reward their people to attain operating success. The company acts as a trusted advisor to management, utilizing its global and board-level corporate experience to achieve big-picture impact through cultural change. Human Capital Consulting Partners analyzes business strategy, issues, and organizational dynamics and implements hands-on, practical, and results-oriented human capital strategies that drive business success. For more information, see www.hccpartners.com or call 215-244-8110.

About Evotec AG

[Evotec](#) is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.